| From Tuesday's close, the average target of $6.25 that 7 analysts are projecting signal a potential upside of 500+%.
From current chart levels, do these targets suggest (Nasdaq: ONCY) is underappreciated?
2.) Oncolytics Biotech® Announces Updated Clinical Data From GOBLET Cohort 4 Demonstrating Activity Of Pelareorep Plus Atezolizumab In Third-Line Anal Cancer.
The GOBLET Cohort 4 shows pelareorep plus atezolizumab delivering an approximate 29% objective response rate in heavily pretreated third-line anal cancer patients, including both complete and partial responses, in a setting with no FDA‑approved options.
Median duration of response of about 17 months highlights deep and durable benefit that far exceeds historical third‑line benchmarks of roughly 10% ORR with limited durability.
These data position Oncolytics Biotech to pursue a clear registration pathway and potential accelerated approval in a difficult indication with high unmet need.
3.) Oncolytics Biotech® Provides Update On Intellectual Property Strategy And Patent Filings.
Oncolytics Biotech is actively expanding intellectual property protection around pelareorep to support long‑term value creation.
A Track 1 prioritized manufacturing patent application filed with the USPTO could, if granted, extend core protection to 2044, meaningfully lengthening pelareorep’s commercial runway.
Planned additional filings on manufacturing innovations and novel methods of use may further extend protection beyond 2044, aligning IP life with pelareorep’s emerging clinical profile in gastrointestinal cancers and strengthening the company’s strategic position with regulators, partners, and shareholders.
4.) Oncolytics Biotech® Announces Promising Efficacy And Translational Data Supporting Pelareorep In KRAS-Mutant Metastatic Colorectal Cancer.
Oncolytics reported a 33% objective response rate when pelareorep was combined with bevacizumab and FOLFIRI in second‑line KRAS‑mutant, MSS metastatic colorectal cancer—tripling historical response rates of approximately 6–11% for Avastin plus FOLFIRI alone.
The regimen also more than doubled progression‑fr-ee and overall survival versus bevacizumab and FOLFIRI, underscoring pelareorep’s potential to reshape outcomes in this notoriously hard‑to‑treat population.
Translational analyses show pelareorep increases KRAS‑mutant–specific T‑cell populations, providing a compelling mechanistic rationale and reinforcing Oncolytics’ vision of pelareorep as a precision immunotherapy in a multi-Bn‑dollar colorectal cancer market.
5.) Oncolytics Biotech® Appoints John McAdory As EVP Of Strategy And Operations And Yujun Wu To Lead Biostatistics.
Oncolytics Biotech has strengthened its management team to support late‑stage development of pelareorep in gastrointestinal cancers.
The appointment of John McAdory as Executive Vice President of Strategy and Operations brings extensive experience running complex, registration‑directed oncology trials, directly aligning with Oncolytics’ move toward pivotal studies in anal, pancreatic, and colorectal cancers.
Adding Yujun Wu as Vice President, Head of Biostatistics, enhances the company’s internal statistical and regulatory capabilities, helping optimize trial design and execution as Oncolytics targets accelerated approval pathways and robust data packages for pelareorep. -----
Officially underway: coverage has begun on Volato Group, Inc. (Nasdaq: SOAR).
Updates will come your way shortly. Keep on the lookout.
All the best, Dane James Editor Market Pulse Today
(Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.)
*MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 02/03/2026 and ending on 02/04/2026 to publicly disseminate information about (ONCY:US) via digital communications. Under this agreement, TD Media LLC has paid Thousand Sun Media LLC seven thousand five hundred USD ("Funds"). These Funds were part of the ninety thousand USD funds that TD Media LLC received from Oncolytics Biotech Inc., the issuer of (ONCY:US).
Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (ONCY:US).
Please see important disclosure information here: https://marketpulsetoday.com/disclosure/oncy-wayo3/#details | 
0 التعليقات:
إرسال تعليق